

---

## ACCELERATED COMMUNICATION

---

# Subtype-Specific Differences in Subcellular Localization of $\alpha_1$ -Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface $\alpha_1$ -Adrenoceptors Irrespective of the Subtype

AKIRA HIRASAWA, TATSUO SUGAWARA, TAKEO AWAJI, KEIKO TSUMAYA, HIROSHI ITO, and GOZOH TSUJIMOTO

*Department of Molecular, Cell Pharmacology, National Children's Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo, 154 Japan (A.H., T.S., T.A., G.T.), and Department of Biological Sciences, Tokyo Institute of Technology, Midori-ku, Yokohama, 226 Japan (K.T., H.I.)*

Received May 27, 1997; Accepted July 29, 1997

---

### SUMMARY

Selective inactivation of  $\alpha_{1B}$ -adrenoceptor (AR) by the site-directed alkylating agent chlorethylclonidine (CEC) has been used as one of major pharmacological criteria to subclassify  $\alpha_1$ -AR; however, the mechanism for the differential CEC sensitivity of the two subtypes is uncertain, and the extent of CEC inactivation varies depending on the treatment employed. In this study, we examined the correlation between the subcellular localization of  $\alpha_1$ -AR subtypes ( $\alpha_{1A}$  and  $\alpha_{1B}$ ) and CEC sensitivity. Constructing  $\alpha_1$ -AR tagged with the FLAG epitope at the amino terminus and/or green fluorescent protein (GFP) at the carboxyl terminus, we examined the subcellular distribution of  $\alpha_1$ -ARs expressed in COS-7 cells. Flow cytometry analysis showed that most populations of GFP-expressing  $\alpha_{1B}$ -AR cells, but very few GFP-expressing  $\alpha_{1A}$ -AR cells, were detected by the anti-amino terminus antibodies. The immunocytochemical

and GFP-fluorescence confocal micrographs showed that  $\alpha_{1A}$ -ARs predominantly localize intracellularly, whereas  $\alpha_{1B}$ -ARs localize on the cell surface. Furthermore, CEC (10  $\mu$ M) treatment of intact cells resulted in an inactivation of approximately 42% of  $\alpha_{1A}$ -ARs and 93% of  $\alpha_{1B}$ -ARs, whereas treatment of the membrane preparations resulted in an inactivation of approximately 83% of  $\alpha_{1A}$ -ARs and 88% of  $\alpha_{1B}$ -ARs, respectively. Together, the results showed that a hydrophilic alkylating agent CEC preferentially inactivates  $\alpha_1$ -AR on the cell surface irrespective of its subtype, and that the subtype-specific subcellular localization rather than the receptor structure is a major determinant for CEC inactivation of  $\alpha_1$ -AR. Subtype-specific subcellular localization suggests an additional class of functional properties that provide new insight into drug action.

---

$\alpha_1$ -ARs play critical roles in the regulation of a variety of physiological processes, such as smooth muscle contraction, myocardial inotropy and chronotropy, and hepatic glucose metabolism (1, 2). Increasing evidence suggests that these physiological responses are regulated by multiple receptor subtypes that are structurally homologous (3, 4). Heterogeneity of  $\alpha_1$ -ARs ( $\alpha_{1A}$  and  $\alpha_{1B}$ ) was first suggested by pharmacological studies based on differential affinity of a variety

of agonist and antagonists, and differential sensitivity to the alkylating agent CEC (5–11). Molecular cloning identified three distinct cDNA encoding  $\alpha_1$ -AR subtypes ( $\alpha_{1a}$ ,  $\alpha_{1b}$ , and  $\alpha_{1d}$ ) (12–17). More recent studies provide evidence supporting the idea that the  $\alpha_{1a}$ -AR (formerly  $\alpha_{1c}$ -AR) cDNA encodes the pharmacological  $\alpha_{1A}$ -AR subtype, whereas the  $\alpha_{1b}$ -AR cDNA clone appears to encode the natively expressed, pharmacologically defined  $\alpha_{1B}$ -AR subtype (18–20).

A selective inactivation of  $\alpha_{1B}$ -AR by CEC has been used as one of major criteria to subclassify the  $\alpha_1$ -AR binding sites and functional responses; however, the mechanism for the preferential inactivation of  $\alpha_{1B}$ -AR by CEC is uncertain (4).

---

This investigation was partially supported by research grants from the Scientific Fund of the Ministry of Education, Science, and Culture of Japan, the Japan Health Science Foundation and Ministry of Human Health and Welfare.

---

**ABBREVIATIONS:** AR, adrenoceptor; CEC, chlorethylclonidine; HEAT, (2- $\beta$ -(4-hydroxyphenyl)-ethylaminomethyl)-tetralone; PBS, phosphate-buffered saline; GFP, green fluorescent protein; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.

---



## Cell Culture and Transfection

COS-7 cells, obtained from the American Type Culture Collection (Rockville, MD), were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The constructs were transfected into COS-7 cells by the electroporation method using Cell-Porator (BRL Life Technologies, Bethesda, MD) according to the manufacturer's instructions, and cells were assayed 48–72 hr after transfection.

## Antibody Preparation

Generation of an anti-peptide antibody (designated as 1B-N1-C) was described previously (23). Briefly, peptide was synthesized corresponding to amino acids 12–27 [peptide: 1B-N1; (C)SAPA-QWGELKDNFTG] of the published hamster  $\alpha_{1B}$ -AR sequence (12), conjugated to the carrier protein keyhole limpet hemocyanin and injected to rabbits. Antisera were screened against the peptides by using cross-dot systems (Sebia, Molineaux, France) and visualized by ABC system (Vector Laboratories, Burlingame, CA). By immunoblotting and immunoprecipitation studies, we confirmed that the antibody detect the  $\alpha_{1B}$ -AR (24).

Antiserum was purified on 1 ml of a protein A-Sepharose CL-4B column (Pharmacia Biotech, Tokyo, Japan) equilibrated with 20 mM phosphate buffer, pH 7.5, and eluted with glycine-HCl buffer (100 mM, pH 2.2), into 1-ml fractions, which were immediately neutralized with 1 M Tris-HCl buffer, pH 8.5. The resulting antibody fractions were concentrated by Centricon 30 microconcentrator (Amicon, Danvers, MA) and stored at  $-20^{\circ}$ .

## Flow Cytometry Analysis

For the flow cytometry analysis with specific antibodies, attached cells were trypsinized and washed twice with PBS. Cells were then incubated for 30 min at  $4^{\circ}$  with the primary antiserum (1B-N1-C, diluted 1/100) or anti-FLAG monoclonal antibody (10  $\mu$ g/ml; Eastman Kodak, New Haven, CT), washed three times with PBS, and incubated with Cy3-conjugated goat anti-rabbit or goat anti-mouse IgG (Chemicon International, Temecura, CA) for 60 min at  $4^{\circ}$ .

Analysis of the cells was performed by using FACScan flow cytometer (Becton Dickinson, Mountain View, CA). To avoid artifacts arising from auto-fluorescence of dead cells and cellular debris, data acquisition was electrically gated for large particles presumably representing intact cells by forward and side scatter. We have used flow cytometry standard setting adjusted to routine double staining techniques employing GFP-associated fluorescence (FL-1) and Cy3 (FL-2) using operating program LYSIS-II. Routinely, data from green fluorescence of  $10^4$  cells were subjected to histogram and dot-plot analysis, and FL-2 fluorescence of GFP-positive cells were compared with the control.

## Laser Scanning Microscope Analysis

**Immunofluorescence detection.** Transfected and untransfected COS-7 cells were seeded at  $1 \times 10^5$  per well of the 8-well Lab tek chamber slide (Nunc, Naperville, CT) in 0.5 ml of medium. Fixation was performed in 80% acetone for 5 min. Cells were then incubated with 0.05% Triton X-100 in PBS. The primary antibodies, 10  $\mu$ g/ml of anti-FLAG monoclonal antibody (Eastman Kodak) and 5  $\mu$ g/ml affinity-purified anti- $\alpha_{1B}$ -AR antibody (1B-N1-C) (24), were brought in PBS containing 10% goat serum and 0.05% Triton X-100, and applied to cells, which were subsequently kept in a humidified chamber for 1 hr at room temperature. Fluorescein isothiocyanate-conjugated goat anti-mouse or anti-rabbit IgG (Chemicon International, Temecura, CA) was diluted 1/200 in PBS containing 2% bovine serum albumin and 0.05% Triton X-100, and applied to cells for 1 hr at room temperature. Cells were then washed twice with PBS, and coverslips were applied using Gel/Mount (Biomed, Foster City, CA). After immunocytochemical staining, cells were examined by using LSM-GB200 laser scanning microscope (Olympus, Tokyo,

Japan) with argon-ion laser set at 488 nm for excitation of fluorescein isothiocyanate.

**GFP detection.** Transfected and untransfected COS-7 cells were seeded at  $1 \times 10^5$  per well of the cover-glass bottom culture dish (MatTek, Ashland, MA) in 2.0 ml of medium. Two days after transfection, cells were washed with PBS and examined using LSM-GB200 within 30 min at room temperature.

## $^{125}$ I-HEAT-Binding Assay

**Membrane preparation.** Membrane preparation of the cells was performed as described previously (16, 17, 27). Briefly, the cells were collected and disrupted by the sonicator (model SONIFIER 250, setting 5 for 8 sec) in ice-cold buffer A (250 mM sucrose, 5 mM Tris-HCl, 1 mM  $MgCl_2$ , pH 7.4) and centrifuged at  $3,000 \times g$  at  $4^{\circ}$  for 10 min to remove nuclei. The supernatant fraction was centrifuged at  $35,000 \times g$  for 20 min at  $4^{\circ}$ . The resulting pellet was resuspended in binding buffer (50 mM Tris-HCl, 12.5 mM  $MgCl_2$ , 10 mM EGTA, pH 7.4), and was frozen at  $-80^{\circ}$  until assay. All buffers contain protein inhibitors of 1 mM phenylmethylsulfonyl fluoride, 100  $\mu$ M benzamidine, 1  $\mu$ g/ml pepstatin A, and 1  $\mu$ g/ml leupeptin.

**$^{125}$ I-HEAT binding.**  $^{125}$ I-HEAT-binding assay was performed as described previously (16, 17, 27). Briefly, membrane aliquots (~10  $\mu$ g of protein) were incubated with  $^{125}$ I-HEAT in a final volume of 250  $\mu$ l of binding buffer for 60 min at  $25^{\circ}$ . The incubation was terminated by adding the ice-cold buffer B and immediately filtering through Whatmann GF/C glass-fiber filters with a Brandel cell harvester (model-30; Brandel, Gaithersburg, MD). Each filter was collected, and the radioactivity was measured. Binding assays were always performed in duplicate, and specific  $^{125}$ I-HEAT binding was determined experimentally from the difference between counts in the absence and presence of 10  $\mu$ M phentolamine.  $B_{max}$  and  $K_d$  values were obtained by fitting rectangular hyperbolic functions to the experimental data, using computer-assisted iterative nonlinear regression analysis. The protein concentration was measured using the BCA protein assay kit (Pierce, Rockford, IL). Values are expressed as the mean  $\pm$  standard deviation.

**CEC treatment.** Intact cell treatment:  $5\text{--}10 \times 10^6$  cells suspended in 1 ml of the buffered salt solution (140 mM NaCl, 4 mM KCl, 1 mM  $MgCl_2$ , 1.25 mM  $CaCl_2$ , 1 mM  $NaH_2PO_4$ , 5 mM HEPES, 11 mM glucose and 0.1% bovine serum albumin, pH 7.4) was incubated with or without CEC (10  $\mu$ M) at  $37^{\circ}$  for 30 min. After incubation, cells were washed three times with the buffered salt solution and used for the binding assay.

**Hypoosmotic membrane treatment:** Membranes prepared from cells were incubated in 1 ml volume of hypotonic buffer (5 mM Tris-HCl, 5 mM EDTA, pH 7.6) with or without CEC (10  $\mu$ M) at  $37^{\circ}$  for 30 min (8, 9). The reactions were stopped by adding 16 ml of ice-cold buffer, and the solution was centrifuged at  $35,000 \times g$  for 20 min at  $4^{\circ}$ . The membranes were washed and resuspended in buffer B, and residual  $^{125}$ I-HEAT binding was assessed.

## Materials

Materials were obtained from the following sources:  $^{125}$ I-HEAT (specific activity, 2200 Ci/mmol; New England Nuclear, Boston, MA); prazosin HCl (Pfizer, Brooklyn, NY); phentolamine mesylate (Ciba-Geigy, Summit, NJ); fetal bovine serum and goat serum (Gibco, Gaithersburg, MD); and Dulbecco's modified Eagle's medium (Nissui, Tokyo, Japan). All other reagents were of the highest analytical grade.

## Results and Discussion

We first compared ligand binding of the  $\alpha_1$ -AR conjugates we constructed with their wild-type  $\alpha_1$ -AR subtype. All constructs were expressed transiently in COS-7 cells to characterize their binding properties to the antagonist  $^{125}$ I-HEAT. The antagonist-binding isotherms for  $\alpha_{1A}$ -FH,  $\alpha_{1A}$ -GFP,  $\alpha_{1A}$ -

TABLE 1  
Comparison of  $K_d$  and  $B_{max}$  of wild-type, epitope-tagged, and GFP-fused  $\alpha_1$ -ARs.

Affinity for  $^{125}$ I-HEAT binding was determined in membrane preparations from cultured COS-7 cells transiently transfected with constructs for epitope-tagged and GFP-fused  $\alpha_1$ -ARs. Each value is the mean of two to three different experiments.

Constructs	$K_d$ nM	$B_{max}$ $\mu$ mol/mg
$\alpha_{1A}$	81.3	3.94
$\alpha_{1A}$ -FH	72.2	1.96
$\alpha_{1A}$ -GFP	80.5	0.88
$\alpha_{1A}$ -FH-GFP	48.3	1.58
$\alpha_{1B}$	86.6	2.13
$\alpha_{1B}$ -GFP	74.5	4.10

FH-GFP and  $\alpha_{1B}$ -GFP conjugates were nearly identical to the wild-type  $\alpha_{1A}$ -AR or  $\alpha_{1B}$ -AR, respectively (Table 1), confirming that epitope tagging and/or GFP fusion in this manner does not perturb normal ligand binding. Receptor subtypes displayed similar transfection efficiencies (assessed by the percentage of transfected cells expressing GFP-associated fluorescence; Fig. 2). Both wild-type and conjugated receptors expressed in COS-7 cells were found to be functional, as a norepinephrine ( $10^{-7}$  M)-induced intracellular free  $Ca^{2+}$  concentration response was observed by using Indo-1 (28) (data

not shown). Although all the receptor conjugates showed similar ligand binding to  $^{125}$ I-HEAT, the tagging technique may have an artifactual effect on receptor folding and sorting. Hence, all experiments below were performed with wild-type receptors in parallel whenever possible.

Using the epitope- and/or GFP-tagged receptors, we characterized the subcellular localization of  $\alpha_1$ -AR subtypes. We used flow cytometry analysis and confocal microscopy analysis of immunolocalization and GFP fluorescence, which enable us to detect the cell surface receptor and also to visualize the subcellular distribution of  $\alpha_1$ -ARs, respectively. First, the cells transfected with  $\alpha_{1A}$ -FH-GFP and  $\alpha_{1B}$ -GFP conjugates were examined by flow cytometry. When transfected, approximately 10–20% of COS-7 cells were positively detected as GFP-associated fluorescence for  $\alpha_{1A}$ -FH-GFP and  $\alpha_{1B}$ -GFP receptors (Fig. 2, A and C). The mean value of fluorescence intensity of  $\alpha_{1B}$ -GFP receptor was noted to be stronger than that of  $\alpha_{1A}$ -FH-GFP or  $\alpha_{1A}$ -GFP (*x*-axis; Fig. 2, A versus C). Then, the cells transfected with  $\alpha_{1A}$ -FH-GFP and  $\alpha_{1B}$ -GFP conjugates were stained by the anti-FLAG monoclonal antibody and by the antibody 1B-N1-C, respectively. Interestingly, as shown in Fig. 2, B and D, most populations of the cells expressing GFP were further detected (an upward shift) by 1B-N1-C (Fig. 2D), whereas very few cells expressing GFP





Fig. 2. Flow cytometry analysis for  $\alpha_1$ -ARs. COS-7 cells transfected with pME- $\alpha_{1A}$ -FH-GFP (A and B) and pME- $\alpha_{1B}$ -GFP (C and D) were analyzed by fluorescence-activated cell sorter flow cytometer. The cells were stained with nonimmune serum (A and C), anti-FLAG antibody (B), or anti-peptide antiserum against the  $\alpha_{1B}$ -amino terminus (D). Results are shown by two-dimensional dot-plot using GFP fluorescence (FL-1: horizontal) and Cy3 labeled secondary antibody (FL-2: vertical). GFP<sup>+</sup>, cells expressing GFP-fused receptor; GFP<sup>-</sup>, cells that do not express GFP-fused receptor. The *x*-axis is relative fluorescence of GFP; *y*-axis is relative fluorescence of Cy3.

were detected by anti-FLAG antibody (no upward shift) (Fig. 2B). The failure for  $\alpha_{1A}$ -GFP-expressing cells to be detected by anti-FLAG monoclonal antibody is not due to the construct or the weak affinity of antibody, because  $\alpha_{1A}$ -FH and  $\alpha_{1A}$ -FH-GFP can be immunostained by the same antibody (as shown below). Additionally, when the empty vector pME18s was transfected, no cell was positively detected as GFP-associated fluorescence or stained by antibodies. The results show that amino terminus of the  $\alpha_{1B}$ -AR can be, but that of  $\alpha_{1A}$ -AR cannot be, detected by the antibody.


We further visually examined the cellular distribution of receptors using fluorescent antibody ( $\alpha_{1A}$ -FH and  $\alpha_{1B}$ -AR) and also the endogenous receptor fluorescence ( $\alpha_{1A}$ -GFP and  $\alpha_{1B}$ -GFP) by fluorescent confocal microscopy. As seen in Fig. 3 (left), immunocytochemical analysis showed that the fluorescence distribution of  $\alpha_{1A}$ -AR is characteristic of the cytoplasmic distribution (enhanced perinuclear fluorescence), whereas that of  $\alpha_{1B}$ -AR is typical of a plasma membrane-labeling pattern. Furthermore, corresponding well with immunocytochemical localization, the fluorescence micrograph of GFP shows that a strong green fluorescence densely localizes in a perinuclear region for  $\alpha_{1A}$ -GFP, whereas fluorescence is diffuse in plasma membranes for  $\alpha_{1B}$ -GFP (Fig. 3, right). Additionally, a similar cytoplasmic distribution was observed for  $\alpha_{1A}$ -FH-GFP by using fluorescent antibody and also endogenous receptor fluorescence, and no fluorescence signal was detected in untransfected cells (data not shown). Together with the results of flow cytometry analysis, these confocal microscopy analyses show that  $\alpha_{1A}$ -AR predomi-

nantly localizes intracellularly, whereas most  $\alpha_{1B}$ -AR localizes on the cell surface.

We showed previously that the transfected  $\alpha_{1A}$ -ARs could be inactivated easily by CEC when treated in membrane preparation, whereas they were relatively resistant to CEC inactivation compared with  $\alpha_{1B}$ -AR when treated in intact cells (17, 29). To examine the correlation between the subcellular localization and the extent of CEC inactivation, we further compared the extent of CEC inactivation when treated in intact cells with that when treated in membrane preparation. As summarized in Fig. 4, CEC ( $10 \mu\text{M}$  30 min) treatment of intact cells reduced the number of  $^{125}\text{I}$ -HEAT binding sites by  $41.8 \pm 12.3\%$ ,  $27.1 \pm 18.1\%$ ,  $37.7 \pm 17.7\%$ , and  $43.7 \pm 17.1\%$  ( $n = 3$  each) in the wild-type  $\alpha_{1A}$ -AR,  $\alpha_{1A}$ -FH,  $\alpha_{1A}$ -GFP, and  $\alpha_{1A}$ -FH-GFP, respectively; on the other hand, by  $86.0 \pm 4.5\%$  and by  $92.6 \pm 1.9\%$  ( $n = 3$  each) in the wild-type  $\alpha_{1B}$ -AR and  $\alpha_{1B}$ -GFP, respectively. In contrast to the intact cell treatment, membrane preparation treatment resulted in a marked reduction of  $^{125}\text{I}$ -HEAT binding sites in  $\alpha_{1A}$ -AR (by  $83.3 \pm 2.5\%$ ,  $n = 5$ ); however, it did not cause any further decrease of  $^{125}\text{I}$ -HEAT binding sites in  $\alpha_{1B}$ -AR (by  $88.2 \pm 4.5\%$ ,  $n = 4$ ). In all cells, the  $K_d$  values to  $^{125}\text{I}$ -HEAT obtained after CEC treatment were not much different from those obtained without CEC treatment (see Fig. 4 legend). Together with the observation that the two  $\alpha_1$ -AR subtypes differentially localize, the results may suggest that a highly hydrophilic alkylating agent CEC inactivates only  $\alpha_1$ -AR on the cell surface irrespective of its subtype; thus, the subtype-specific cellular distribution rather



**Fig. 3.** The immunocytochemical and GFP fluorescence confocal micrographs of the  $\alpha_{1A}$ -AR and  $\alpha_{1B}$ -AR in COS-7 cells. Immunocytochemical staining with anti-peptide antiserum (1B-N1-C) and anti-FLAG antibody were performed in the pME- $\alpha_{1A}$ -FH (left) or pME- $\alpha_{1B}$  (right)-transfected COS-7 cells. GFP fluorescence was also observed in the pME- $\alpha_{1A}$ -GFP (left) or pME- $\alpha_{1B}$ -GFP (right)-transfected COS-7 cells in intact condition. Bottom, cells were also observed by electrical pseudo-differential interference contrast (DIC) image. Scale bar,  $10 \mu\text{m}$ .



**Fig. 4.** Comparison of CEC inactivation by intact cell treatment and by membrane preparation treatment. For the intact cell treatment, COS-7 cells incubated with or without CEC ( $10 \mu\text{M}$ ) at  $37^\circ$  for 30 min. After incubation, cells were washed three times with the buffered salt solution and used for the binding assay. In the membrane preparation treatment, membranes prepared from cells were incubated in hypotonic buffer (5 mM Tris-HCl, 5 mM EDTA, pH 7.6) with CEC ( $10 \mu\text{M}$ ) at  $37^\circ$  for 30 min and residual  $^{125}\text{I}$ -HEAT binding was assessed. The mean  $K_d$  values obtained in cells after CEC treatment were 48.5, 142, 33.0, 37.0, 28.8, and 67.0 nM,  $n = 2-3$ , in the wild-type  $\alpha_{1A}$ -AR,  $\alpha_{1A}$ -FH,  $\alpha_{1A}$ -GFP,  $\alpha_{1A}$ -FH-GFP, wild-type  $\alpha_{1B}$ -AR, and  $\alpha_{1B}$ -GFP, respectively. The results are expressed as the decrease in percentage of the control  $^{125}\text{I}$ -HEAT binding. The values correspond to the mean  $\pm$  standard deviation of at least three independent experiments. \*, CEC inactivation was significantly different from that obtained in the intact cell treatment (unpaired  $t$  test,  $p < 0.05$ ).

than the receptor structure is a major determinant for CEC inactivation of  $\alpha_1$ -AR.

As indicated in the introductory material, three  $\alpha_1$ -AR cDNA clones have been isolated, but their relationship to the pharmacologically defined  $\alpha_{1A}$ - and  $\alpha_{1B}$ -AR subtypes has been controversial. More recently, based on the comparison of the  $K_i$  values of native  $\alpha_1$ -ARs from tissues with those of cloned  $\alpha_1$ -ARs, and on the comparison of the tissue distribution of native  $\alpha_1$ -ARs assessed by using subtype-selective drugs with that of mRNA expression of cloned receptors (18, 19), the IUPHAR Committee on the Classification of Adrenoceptor recommended that the  $\alpha_{1a}$ -AR (formerly  $\alpha_{1c}$ -AR) cDNA encodes the pharmacological  $\alpha_{1A}$ -AR subtype, whereas the  $\alpha_{1b}$ -AR cDNA clone appears to encode the natively expressed, pharmacologically defined  $\alpha_{1B}$ -AR subtype (20). In this report, we demonstrated that  $\alpha_{1A}$ -AR predominantly localizes intracellularly, whereas most of  $\alpha_{1B}$ -ARs localize on the cell surface, and further indicate that the subtype-specific difference in receptor distribution appears to be reflected by inactivation of the highly hydrophilic alkylating agent CEC. The current results emphasize that one must be cautious in interpreting the data obtained by using CEC inactivation to study the functional role of each subtype.

Differential distribution of receptor subtypes appears to be generally observed for G protein-coupled receptors. von Zastrow *et al.* (30) and Saunders *et al.* (31) showed that subtype-specific different localization of  $\alpha_2$ -AR subtypes. Thus, subtype-specific sorting comprises another important parameter, in addition to ligand binding affinity and G pro-

tein-coupling specificity, which may functionally differentiate receptor subtypes, thereby increase signal diversity. It is postulated that subtype-specific sorting might segregate individual receptors, G proteins, and effectors into functionally specialized microdomains (compartmentalization) and specify the signal transduction (30). Subtype-specific sorting may play an important role not only in increasing the signal diversity but also in the regulatory properties of receptor. Subtype-specific differences in susceptibility to agonist-promoted desensitization (and receptor phosphorylation) appeared to be well correlated with the cellular localization of receptor subtype; thus,  $\alpha_2$ -C10-ARs and  $\alpha_{1B}$ -ARs, which localize in the plasma membrane, are more easily desensitized compared with  $\alpha_2$ -C4-ARs and  $\alpha_{1A}$ -ARs, which predominantly localize intracellularly (32, 33). It is also suggested that intracellular receptors could serve as a reserve pool for delivery to the plasma membrane (30). In support of this view, we had previously shown a sizable pool of spare receptor for  $\alpha_{1A}$ -AR and an absence of a receptor reserve for  $\alpha_{1B}$ -AR by using the phenoxybenzamine-inactivation method (9, 10). Such internal stores could contribute to the rapid up-regulation of G protein-coupled receptor observed in physiological and pathophysiological conditions (34, 35). Further studies are clearly required to clarify the functional role of the subtype-specific subcellular localization.

In conclusion, we demonstrate for the first time that  $\alpha_1$ -AR subtypes have differential subcellular localization, which appears to be a major determinant for CEC inactivation of  $\alpha_1$ -AR. Thus, receptor subtype-specific localization suggests an additional functional properties that may explain the signal and functional diversity, and moreover it is of importance in assessing drug action. With the availability of experimental system as exemplified in the present study, elucidation of the molecular mechanism and function of the subtype-specific subcellular distribution may provide new insight into signal transduction as well as drug action.

#### Acknowledgments

We thank Dr. M. Kataoka (Department of Molecular and Cell Pharmacology) and Dr. H. Takahashi for generously providing GFP cDNA and for helpful discussion.

#### References

- Nichols, J. A., and J. R. R. Ruffolo. Functions mediated by  $\alpha$ -adrenoceptors, in  $\alpha$ -adrenoceptors: molecular biology, biochemistry, and pharmacology, in *Progress in Basic and Molecular Pharmacology* (J. R. R. Ruffolo, ed.). Karger, Basel, 115-179 (1991).
- Hoffman, B. B., and R. J. Lefkowitz. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists, in *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. G. Gilman, eds.). McGraw-Hill, New York, 199-248 (1996).
- Knowlton, K. U., M. C. Michel, M. Itani, H. E. Shubeita, K. Ishihara, J. H. Brown, and K. R. Chien. The  $\alpha_{1A}$ -adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. *J. Biol. Chem.* **268**:15374-15380 (1993).
- Minneman, K. P., and T. A. Esbenshade.  $\alpha_1$ -Adrenergic receptor subtypes. *Annu. Rev. Pharmacol. Toxicol.* **34**:117-133 (1994).
- McGrath, J. C. Evidence for more than one type of post-junctional  $\alpha$ -adrenoceptor. *Biochem. Pharmacol.* **31**:467-484 (1982).
- Morrow, A. L., and I. Creese. Characterization of  $\alpha_1$  1-adrenergic receptor subtypes in rat brain: a reevaluation of [ $^3\text{H}$ ]WB4104 and [ $^3\text{H}$ ]prazosin binding. *Mol. Pharmacol.* **29**:321-330 (1986).
- Han, C., P. W. Abel, and K. P. Minneman.  $\alpha_1$ -Adrenoceptor subtypes linked to different mechanisms for increasing intracellular  $\text{Ca}^{2+}$  in smooth muscle. *Nature (Lond.)* **329**:333-335 (1987).
- McGrath, J., and V. Wilson.  $\alpha$ -Adrenoceptor subclassification by classical and response-related methods: same question, different answers. *Trends Pharmacol. Sci.* **9**:162-165 (1988).

9. Tsujimoto, G., A. Tsujimoto, E. Suzuki, and K. Hashimoto. Glycogen phosphorylase activation by two different  $\alpha_1$ -adrenergic receptor subtypes: methoxamine selectively stimulates a putative  $\alpha_{1a}$ -adrenergic receptor subtype ( $\alpha_{1a}$ ) that couples with  $\text{Ca}^{2+}$  influx. *Mol. Pharmacol.* **36**:166–176 (1989).
10. Suzuki, E., G. Tsujimoto, K. Tamura, and K. Hashimoto. Two pharmacologically distinct  $\alpha_1$ -adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different  $\text{Ca}^{2+}$  signalling mechanism and plays a different physiological role. *Mol. Pharmacol.* **38**:725–736 (1990).
11. Shimura, H., T. Endo, G. Tsujimoto, K. Watanabe, K. Hashimoto, and T. Onaya. Characterization of  $\alpha_1$ -adrenergic receptor subtypes linked to iodide efflux in rat FRTL cells. *J. Endocrinol.* **124**:433–441 (1990).
12. Cotecchia, S., D. A. Schwinn, R. R. Randall, R. J. Lefkowitz, M. G. Caron, and B. K. Kobilka. Molecular cloning and expression of the cDNA for the hamster  $\alpha_1$ -adrenergic receptor. *Proc. Natl. Acad. Sci. USA* **85**:7159–7163 (1988).
13. Schwinn, D. A., J. W. Lomasney, W. Lorenz, P. J. Szklut, R. J. Freneau, F. T. Yang, M. G. Caron, R. J. Lefkowitz, and S. Cotecchia. Molecular cloning and expression of the cDNA for a novel  $\alpha_1$ -adrenergic receptor subtype. *J. Biol. Chem.* **265**:8183–8189 (1990).
14. Lomasney, J. W., S. Cotecchia, W. Lorenz, W. Y. Leung, D. A. Schwinn, F. T. Yang, M. Brownstein, R. J. Lefkowitz, and M. G. Caron. Molecular cloning and expression of the cDNA for the  $\alpha_{1A}$ -adrenergic receptor. The gene for which is located on human chromosome 5. *J. Biol. Chem.* **266**:6365–6369 (1991).
15. Perez, D. M., M. T. Piascik, and R. M. Graham. Solution-phase library screening for the identification of rare clones: isolation of an  $\alpha_1$ -adrenergic receptor cDNA. *Mol. Pharmacol.* **40**:876–883 (1991).
16. Hirasawa, A., K. Horie, T. Tanaka, K. Takagaki, M. Murai, J. Yano, and G. Tsujimoto. Cloning, functional expression and tissue distribution of human cDNA for the  $\alpha_{1C}$ -adrenergic receptor. *Biochem. Biophys. Res. Commun.* **195**:902–909 (1993).
17. Hirasawa, A., K. Shibata, K. Horie, Y. Takei, K. Obika, T. Tanaka, N. Muramoto, K. Takagaki, J. Yano, and G. Tsujimoto. Cloning, functional expression and tissue distribution of human  $\alpha_{1C}$ -adrenoceptor splice variants. *FEBS Lett.* **363**:256–260 (1995).
18. Perez, D. M., M. T. Piascik, N. Malik, R. Gaivin, and R. M. Graham. Cloning, expression, and tissue distribution of the rat homolog of the bovine  $\alpha_{1C}$ -adrenergic receptor provide evidence for its classification as the  $\alpha_{1A}$  subtype. *Mol. Pharmacol.* **46**:823–831 (1994).
19. Laz, T. M., C. Forray, K. E. Smith, J. A. Bard, P. J. Vaysse, T. A. Branchek, and R. L. Weinshank. The rat homologue of the bovine  $\alpha_{1C}$ -adrenergic receptor shows the pharmacological properties of the classical  $\alpha_{1A}$  subtype. *Mol. Pharmacol.* **46**:414–422 (1994).
20. Hieble, J. P., D. B. Bylund, D. E. Clarke, D. C. Eikenburg, S. Z. Langer, R. J. Lefkowitz, K. P. Minneman, and R. J. Ruffolo. International Union of Pharmacology. X. Recommendation for nomenclature of  $\alpha_1$ -adrenoceptors: consensus update. *Pharmacol. Rev.* **47**:267–270 (1995).
21. Auguet, M., S. Delaflotte, and P. E. Chabrier. Different  $\alpha_1$ -adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. *Eur. J. Pharmacol.* **287**:153–161 (1995).
22. Buscher, R., C. Heeks, K. Taguchi, and M. C. Michel. Comparison of guinea-pig, bovine and rat  $\alpha_1$ -adrenoceptor subtypes. *Br. J. Pharmacol.* **117**:703–711 (1996).
23. Hoo, K. H., C. Y. Kwan, and E. E. Daniel. Investigation of  $\alpha_1$ -adrenoceptor subtypes in canine aorta, using alkylating agents. *Can. J. Physiol. Pharmacol.* **72**:97–103 (1994).
24. Hirasawa, A., K. Tsumaya, T. Awaji, K. Shibata, N. Homma, T. Shinomiya, and G. Tsujimoto. Flow cytometry analysis of  $\alpha_1$ -adrenoceptor subtypes. *FEBS Lett.* **386**:141–148 (1996).
25. Foglar, R., K. Shibata, K. Horie, A. Hirasawa, and G. Tsujimoto. Use of recombinant  $\alpha_1$ -adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. *Eur. J. Pharmacol.* **288**:201–207 (1995).
26. Lattion, A. L., D. Diviani, and S. Cotecchia. Truncation of the receptor carboxyl terminus impairs agonist-dependent phosphorylation and desensitization of the  $\alpha_{1B}$ -adrenergic receptor. *J. Biol. Chem.* **269**:22887–22893 (1994).
27. Shibata, K., R. Foglar, K. Horie, K. Obika, A. Sakamoto, S. Ogawa, and G. Tsujimoto. KMD-3213, a novel, potent,  $\alpha_{1A}$ -adrenoceptor-selective antagonist: characterization using recombinant human  $\alpha_1$ -adrenoceptors and native tissues. *Mol. Pharmacol.* **48**:250–258 (1995).
28. Awaji, T., S. Izumi, K. Horie, A. Hirasawa, and G. Tsujimoto.  $\alpha_{1B}$ -Adrenoceptor-mediated calcium oscillation is specific for the S phase in cell cycle and dependent on the extracellular calcium. *Biochem. Biophys. Res. Commun.* **224**:80–86 (1996).
29. Esbenschade, T. A., A. Hirasawa, G. Tsujimoto, T. Tanaka, J. Yano, K. P. Minneman, and T. J. Murphy. Cloning of the human  $\alpha_{1A}$ -adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. *Mol. Pharmacol.* **47**:977–985 (1995).
30. von Zastrow, M., R. Link, D. Daunt, G. Barsh, and B. Kobilka. Subtype-specific differences in the intracellular sorting of G protein-coupled receptors. *J. Biol. Chem.* **268**:763–766 (1993).
31. Saunders, C., J. R. Keefer, A. P. Kennedy, J. N. Wells, and L. E. Limbird. Receptors coupled to pertussis toxin-sensitive G-proteins traffic to opposite surfaces in Madin-Darby canine kidney cells.  $\alpha_1$ -adenosine receptors achieve apical and  $\alpha_{2A}$  adrenergic receptors achieve basolateral localization. *J. Biol. Chem.* **271**:995–1002 (1996).
32. Suzuki, E., G. Tsujimoto, and K. Hashimoto. Different desensitization mechanisms of two  $\alpha_1$ -adrenoceptor subtypes in the contraction of rabbit aorta. *Br. J. Clin. Pharmacol.* **30**(Suppl. 1):121S–124S (1990).
33. Kurose, H., and R. J. Lefkowitz. Differential desensitization and phosphorylation of three cloned and transfected  $\alpha$  2-adrenergic receptor subtypes. *J. Biol. Chem.* **269**:10093–9 (1994).
34. Maisel, A. S., H. J. Motulsky, and P. A. Insel. Externalization of  $\beta$ -adrenergic receptors promoted by myocardial ischemia. *Science (Washington D. C.)* **230**:183–6 (1985).
35. Maisel, A. S., H. J. Motulsky, and P. A. Insel. Propranolol treatment externalizes  $\beta$ -adrenergic receptors in guinea pig myocardium and prevents further externalization by ischemia. *Circ. Res.* **60**:108–12 (1987).

---

**Send reprint requests to:** Gozoh Tsujimoto, M.D., Ph. D., Department of Molecular, Cell Pharmacology, National Children's Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo, 154 Japan. E-mail: gtsujimoto@nch.go.jp

---